Disruption without interruption: Transitioning Rare Disease HUB & NCP Programs

Article

Sponsored Content

Transitioning a rare disease HUB or NCP program to a rare-focused partner can yield major service quality improvements without program disruption.

Newsletter

Stay ahead in the life sciences industry with Pharmaceutical Commerce, the latest news, trends, and strategies in drug distribution, commercialization, and market access.

Recent Videos
Related Content
© 2025 MJH Life Sciences

All rights reserved.